loading
전일 마감가:
$1.07
열려 있는:
$1.06
하루 거래량:
768.84K
Relative Volume:
0.37
시가총액:
$17.53M
수익:
-
순이익/손실:
$-11.90M
주가수익비율:
-0.00563
EPS:
-206.0125
순현금흐름:
$-12.75M
1주 성능:
+16.19%
1개월 성능:
+10.70%
6개월 성능:
-25.72%
1년 성능:
-16.57%
1일 변동 폭
Value
$1.0599
$1.175
1주일 범위
Value
$0.953
$1.19
52주 변동 폭
Value
$0.1131
$3.95

Allarity Therapeutics Inc Stock (ALLR) Company Profile

Name
명칭
Allarity Therapeutics Inc
Name
전화
401-426-4664
Name
주소
24 SCHOOL ST., 2ND FLOOR, BOSTON
Name
직원
7
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
ALLR's Discussions on Twitter

ALLR을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ALLR
Allarity Therapeutics Inc
1.1552 17.53M 0 -11.90M -12.75M -206.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
506.17 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.91 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
631.50 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.10 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
249.91 24.70B 3.81B -644.79M -669.77M -6.24

Allarity Therapeutics Inc 주식(ALLR)의 최신 뉴스

pulisher
11:33 AM

The Psychology of Allarity Therapeutics Inc Inc. (ALLR) Price Performance: Understanding Market Sentiment - investchronicle.com

11:33 AM
pulisher
07:34 AM

Upward Trajectory: Allarity Therapeutics Inc (ALLR) Posts a Slidee, Closing at 1.07 - DWinneX

07:34 AM
pulisher
Apr 28, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 28, 2025
pulisher
Apr 25, 2025

Allarity unveils new multiple myeloma treatment predictor - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

Allarity unveils new multiple myeloma treatment predictor By Investing.com - Investing.com India

Apr 25, 2025
pulisher
Apr 25, 2025

Healthy Upside Potential: Allarity Therapeutics Inc (ALLR) - Sete News

Apr 25, 2025
pulisher
Apr 25, 2025

Allarity Therapeutics Presents Novel Drug Response - GlobeNewswire

Apr 25, 2025
pulisher
Apr 25, 2025

Novel AI Predictor Identifies Multiple Myeloma Patients for Targeted Treatment | ALLR Stock News - Stock Titan

Apr 25, 2025
pulisher
Apr 23, 2025

Ratios Revealed: Decoding Allarity Therapeutics Inc (ALLR)’s Financial Health - DWinneX

Apr 23, 2025
pulisher
Apr 22, 2025

How to interpret Allarity Therapeutics Inc (ALLR)’s stock chart patterns - uspostnews.com

Apr 22, 2025
pulisher
Apr 21, 2025

Allarity Therapeutics Inc (ALLR) Stock: The Story of a 52-Week Stock Range - investchronicle.com

Apr 21, 2025
pulisher
Apr 16, 2025

Allarity Therapeutics Restructures Board of Directors - TipRanks

Apr 16, 2025
pulisher
Apr 14, 2025

ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PR Newswire

Apr 14, 2025
pulisher
Apr 10, 2025

Allarity Therapeutics stock hits 52-week low at $0.67 - Investing.com

Apr 10, 2025
pulisher
Apr 09, 2025

Allarity Therapeutics stock hits 52-week low at $0.67 By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 08, 2025

There is no way Allarity Therapeutics Inc (ALLR) can keep these numbers up - Sete News

Apr 08, 2025
pulisher
Apr 08, 2025

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Investors to Contact the Firm Today! - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 08, 2025

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Stockholders to Contact the Firm! - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 04, 2025

Allarity Therapeutics Inc (ALLR) Is A Good Stock To Invest In - Stocksregister

Apr 04, 2025
pulisher
Apr 03, 2025

Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Bright Minds Biosciences (NASDAQ:DRUG) - Defense World

Apr 03, 2025
pulisher
Apr 02, 2025

ALLR Stockholders Have Opportunity to Lead Allarity Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 01, 2025

US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday - Benzinga

Apr 01, 2025
pulisher
Apr 01, 2025

Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - The Manila Times

Apr 01, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Allarity's Cancer Drug Shows 17-Month Benefit as Cash Runway Extends to 2027 - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics Inc. (ALLR) reports earnings - qz.com

Mar 31, 2025
pulisher
Mar 31, 2025

Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update - The AM Reporter

Mar 31, 2025
pulisher
Mar 26, 2025

Allarity Therapeutics (NASDAQ:ALLR) Trading 11% Higher – Still a Buy? - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

Allarity Therapeutics probes potential stock manipulation By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 24, 2025

Allarity Therapeutics probes potential stock manipulation - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 24, 2025
pulisher
Mar 24, 2025

Allarity Takes Bold Action Against Market Manipulation: Launches High-Tech Trading Investigation - Stock Titan

Mar 24, 2025
pulisher
Mar 20, 2025

Investigation announced for Long-Term Investors in shares - openPR.com

Mar 20, 2025
pulisher
Mar 19, 2025

ALLR Shareholders Are Encouraged To Join Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm - MENAFN.COM

Mar 19, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Presents Positive Phase 2 Data For Stenoparib In Advanced Ovarian Cancer - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - The Manila Times

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity reports promising ovarian cancer trial results - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in ... - The Bakersfield Californian

Mar 17, 2025
pulisher
Mar 17, 2025

Breakthrough: New Cancer Drug Achieves 10-Month Complete Response in Advanced Ovarian Cancer Patients - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire

Mar 17, 2025
pulisher
Mar 17, 2025

Can you now get a good deal on Allarity Therapeutics Inc’s shares? - uspostnews.com

Mar 17, 2025
pulisher
Mar 14, 2025

ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PrimePublishers.com

Mar 14, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics settles SEC investigation By Investing.com - Investing.com Australia

Mar 13, 2025
pulisher
Mar 13, 2025

SEC Says Allarity Leaders Hid FDA Issue Before Record Stock Drop - news.bloombergtax.com

Mar 13, 2025
pulisher
Mar 13, 2025

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission - GlobeNewswire

Mar 13, 2025

Allarity Therapeutics Inc (ALLR) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.90
price up icon 1.36%
$69.80
price up icon 0.31%
$32.42
price down icon 0.60%
$24.00
price up icon 0.25%
$103.85
price down icon 0.51%
biotechnology ONC
$249.09
price down icon 0.47%
자본화:     |  볼륨(24시간):